Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2020 | TOURMALINE-MM4: oral ixazomib maintenance for myeloma

Meletios Dimopoulos • 3 Jun 2020
EHA 2020
Multiple Myeloma Ixazomib
TOURMALINE-MM4

Meletios Dimopoulos, MD, Kapodistrian University of Athens School of Medicine, Athens, Greece, discusses TOURMALINE-MM4 (NCT02312258), a Phase III trial of oral ixazomib maintenance therapy in participants with newly diagnosed multiple myeloma not treated with stem cell transplantation. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Meletios Dimopoulos

Linvoseltamab with daratumumab or isatuximab in heavily pretreated patients with multiple myeloma
1:19
Linvoseltamab with daratumumab or isatuximab in heavily pretreated patients with multiple myeloma
Meletios Dimopoulos • 7 Dec 2025
Long-term follow-up of ECWM-1: dexamethasone, rituximab, and cyclophosphamide +/- bortezomib in WM
0:51
Long-term follow-up of ECWM-1: dexamethasone, rituximab, and cyclophosphamide +/- bortezomib in WM
Meletios Dimopoulos • 7 Dec 2025
Long-term follow-up of belantamab mafodotin plus pomalidomide and dexamethasone in myeloma: DREAMM-8
1:07
Long-term follow-up of belantamab mafodotin plus pomalidomide and dexamethasone in myeloma: DREAMM-8
Meletios Dimopoulos • 7 Dec 2025
MagnetisMM-6 trial cohort G data: assessing EDR in transplant-ineligible newly diagnosed myeloma
2:08
MagnetisMM-6 trial cohort G data: assessing EDR in transplant-ineligible newly diagnosed myeloma
Meletios Dimopoulos • 12 Jun 2025

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Meletios Dimopoulos • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Meletios Dimopoulos • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Meletios Dimopoulos • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Meletios Dimopoulos • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals